Type Condition

Bowling Green, KY

194 Clinical Trials near Bowling Green, KY

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Iron Supplementation for Heart Failure

Bowling Green, Kentucky
The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth. Participants must have heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) and a transferrin-saturation (TSAT) level below 20 percent. The main questions the study will answer are: 1. Does IV iron raise walking distance on a 6-minute walk test more than oral iron after 24 weeks? 2. Does IV iron improve symptoms and quality of life more than oral iron? 3. How do the two treatments compare for safety, side effects, and hospital readmissions/ mortality? Researchers will compare IV ferric carboxymaltose with oral ferrous sulfate to see which option helps people feel and function better. What participants will do * Be randomly assigned by (like flipping a coin) to IV iron or oral iron. * Receive either a one-time IV iron infusion (with possible repeat at 12 weeks) or take iron pills twice each day for 24 weeks. * Visit the infusion clinic at 6 weeks for second dose of IV iron if needed. * Visit the clinic at 12 weeks for a follow-up to gather follow-up data including 1. A 6-minute walk test 2. Brief symptom and quality-of-life surveys 3. Blood tests to measure serum iron, ferritin, and transferrin saturation This study will help doctors decide whether IV or oral iron is the safer, more effective way to treat iron deficiency in people with heart failure in our local community.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

250 Participants Needed

Lebrikizumab for Eczema

Bowling Green, Kentucky
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:12+

200 Participants Needed

Tirzepatide for Psoriasis and Obesity

Bowling Green, Kentucky
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

200 Participants Needed

TAK-503 for ADHD

Bowling Green, Kentucky
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:6 - 17

396 Participants Needed

EVO756 for Eczema

Bowling Green, Kentucky
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

ORKA-001 for Plaque Psoriasis

Bowling Green, Kentucky
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

80 Participants Needed

ATI-045 for Eczema

Bowling Green, Kentucky
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

96 Participants Needed

Tibulizumab for Hidradenitis Suppurativa

Bowling Green, Kentucky
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

180 Participants Needed

Barzolvolimab for Eczema

Bowling Green, Kentucky
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

Barzolvolimab for Prurigo Nodularis

Bowling Green, Kentucky
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

ADX-914 for Severe Alopecia Areata

Bowling Green, Kentucky
This trial tests ADX-914, an injectable medication, in adults with severe hair loss due to Alopecia Areata. The treatment likely works by calming the immune system to help hair grow back. Delgocitinib has shown effectiveness in other inflammatory skin conditions and is being explored for its potential in treating alopecia areata.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

75 Participants Needed

BLU-808 for Chronic Urticaria

Bowling Green, Kentucky
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

105 Participants Needed

MZE829 for Kidney Disease

Bowling Green, Kentucky
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

56 Participants Needed

AVTX-009 for Hidradenitis Suppurativa

Bowling Green, Kentucky
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

250 Participants Needed

APG777 for Eczema

Bowling Green, Kentucky
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

431 Participants Needed

mRNA Vaccine for Acne

Bowling Green, Kentucky
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a Core Study followed by an optional Long-Term Extension (LTE). The Core Study will consist of a Sentinel Cohort A paired with a Main Cohort, evaluating the safety and efficacy of the 2-administration regimen and a Sentinel Cohort B, evaluating the safety of the 3- administration regimen. The Sentinel Cohorts will assess the safety of the dose levels and regimens in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long-term effects of the vaccine.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 45

260 Participants Needed

Eltrekibart for Hidradenitis Suppurativa

Bowling Green, Kentucky
This trial is testing a new medication called eltrekibart to find the most effective treatment for adults with moderate-to-severe hidradenitis suppurativa. The goal is to see if it can safely and effectively reduce symptoms by targeting inflammation pathways.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

352 Participants Needed

Ruxolitinib Cream for Hidradenitis Suppurativa

Bowling Green, Kentucky
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:12 - 75

24 Participants Needed

Ruxolitinib Cream for Prurigo

Bowling Green, Kentucky
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65

23 Participants Needed

Brief Intervention for Alcohol Use Disorder

Bowling Green, Kentucky
This proposal seeks to improve a mobile-based brief intervention for young adults who engage in heavy alcohol use and have experienced interpersonal trauma. The enhancement involves incorporating adaptive coping strategies to address trauma-related distress and engaging peer coaches following the intervention to support sustained treatment effects. Participants will be randomly assigned to receive either the enhanced intervention with peer coaching or a standard version of the brief intervention. Follow-up assessments will be conducted at 3 and 6 months after the intervention. The research team expects that the trauma-informed and peer-supported brief intervention (TIPS-BI) will have low dropout rates, be well-received by participants, and lead to greater reductions in alcohol use than the standard brief intervention.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 29

190 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

Handgrip Therapy for High Blood Pressure

Bowling Green, Kentucky
The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not currently taking antihypertensive medications. Half of the study subjects will also be randomized to record blood pressure at home throughout the study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22+

160 Participants Needed

Mobile Intervention for Drunk Driving

Bowling Green, Kentucky
Substance-Impaired Driving among emerging adults remains a significant public health concern and may be the single riskiest substance-related outcome among young adults. Brief Interventions (BIs) have been shown to reduce alcohol-impaired driving among this age group, but are not often implemented - despite their demonstrated efficacy - because it is not economically feasible to deliver in-person BIs to all emerging adult substance users. The present study will be the first to examine whether a text-messaging-based cannabis-impaired driving BI significantly decreases cannabis-impaired driving among emerging adult cannabis users compared to an informational control. Participants will be 240 emerging adults who endorse driving after cannabis use (or combined alcohol and cannabis use) at least three times in the past 3 months. After completing baseline measures, participants will be randomly assigned to receive either: a) substance use information, b) a substance-impaired driving personalized feedback intervention, or c) a substance-impaired driving personalized feedback intervention plus interactive text messages. Participants will complete outcome measures 3 and 6 months post-intervention. Repeated measures mixed modeling analyses will be used to determine whether the intervention significantly reduces substance-impaired driving over time. The project has two specific aims: 1) to evaluate a text based cannabis-impaired driving intervention in a randomized clinical trial, and 2) to determine whether the use of interactive text-messages sustains intervention effects over time.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 29

240 Participants Needed

Orforglipron for Type 2 Diabetes and Obesity

Bowling Green, Kentucky
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2749 Participants Needed

Retatrutide for Obesity

Bowling Green, Kentucky
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

10000 Participants Needed

Lepodisiran for Cardiovascular Disease

Bowling Green, Kentucky
This trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

16700 Participants Needed

Tozorakimab for COPD

Bowling Green, Kentucky
This trial tests an injection called tozorakimab for adults with frequent or severe COPD flare-ups. The drug aims to reduce inflammation and prevent these flare-ups.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

1454 Participants Needed

Tirzepatide for Obesity

Bowling Green, Kentucky
This trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

15374 Participants Needed

Tozorakimab for COPD

Bowling Green, Kentucky
This trial is testing injections of a drug called tozorakimab in adults with COPD who have frequent flare-ups. These patients are already on other inhaled treatments but still experience significant symptoms. The drug aims to reduce lung inflammation and prevent these flare-ups.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

1172 Participants Needed

Inclisiran for Cardiovascular Disease

Bowling Green, Kentucky
This trial is testing inclisiran, an injectable drug, on people with heart disease who are already on strong cholesterol-lowering medications. The goal is to see if inclisiran can further reduce the risk of heart attacks and strokes by lowering bad cholesterol levels. Participants will receive the injection periodically. Inclisiran works by significantly reducing bad cholesterol levels.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

17004 Participants Needed

Lasmiditan for Pediatric Migraine

Bowling Green, Kentucky
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17

1000 Participants Needed

123...7

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Bowling Green, KY pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Bowling Green, KY work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Bowling Green, KY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Bowling Green, KY is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Bowling Green, KY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Bowling Green, KY?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Bowling Green, KY?

Most recently, we added Valproic Acid for Traumatic Brain Injury, Ruxolitinib Cream for Hidradenitis Suppurativa and Deucravacitinib for Plaque Psoriasis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Kentucky

Anxiety Clinical Trials in Kentucky

Schizophrenia Clinical Trials in Kentucky

ADHD Clinical Trials in Kentucky

Bipolar Disorder Clinical Trials in Kentucky

Multiple Sclerosis Clinical Trials in Kentucky

Autism Clinical Trials in Kentucky

Treatment Resistant Depression Clinical Trials in Kentucky

Borderline Personality Disorder Clinical Trials in Kentucky

Social Anxiety Disorder Clinical Trials in Kentucky

Parkinson's Disease Clinical Trials in Kentucky

Alzheimer's Disease Clinical Trials in Kentucky

By Location

Clinical Trials near Louisville, KY

Clinical Trials near Lexington, KY

Clinical Trials near Owensboro, KY

Clinical Trials near Paducah, KY

Clinical Trials near Bardstown, KY

Clinical Trials near Edgewood, KY

Clinical Trials near Madisonville, KY

Clinical Trials near Bowling Green, KY

Clinical Trials near Corbin, KY

Clinical Trials near Crestview Hills, KY

Clinical Trials near Hazard, KY

Clinical Trials near Elizabethtown, KY

Other People Viewed

By Subject

205 Clinical Trials near Arlington Heights, IL

40 Psoriasis Trials near Austin, TX

174 Clinical Trials near Ashland, OR

56 Psoriasis Trials near Boston, MA

214 Clinical Trials near Arlington, TX

58 Psoriasis Trials near Lancaster, CA

48 Psoriasis Trials near San Diego, CA

83 Clinical Trials near Kentucky

197 Clinical Trials near Crestview Hills, KY

Top Clinical Trials near Bowling Green, OH

Top Clinical Trials near Green Bay, WI

Top Clinical Trials near Green Valley, AZ

By Trial

Lutikizumab for Hidradenitis Suppurativa

Sonelokimab for Hidradenitis Suppurativa

Green Tea for Prostate Cancer

Tibulizumab for Hidradenitis Suppurativa

Green Light Therapy for Chronic Pain

Green Activity Program for Dementia

ICG Guided Surgery for Cancer

Mindfulness Training for Pregnancy-Related Hypertension

Selumetinib for Pediatric Brain Cancer

Delgocitinib Cream for Palmoplantar Pustulosis

Physical Activity and Nutrition Program for Cognition

Smartphone App for Ear Infection

Related Searches

Top Clinical Trials near Bozeman, MT

Top Clinical Trials near Braintree, MA

Top Clinical Trials near Brecksville, OH

Top Clinical Trials near Bremerton, WA

Semaglutide for Preventing Weight Gain After Liver Transplant

Long-Term Safety of Filgotinib for Rheumatoid Arthritis

Lung Ultrasound for Shortness of Breath

Low-Processed Food Diet for Healthy Eating

Wearable Technology for Epilepsy

Breathe Easier+ for Lung Cancer Survivors

Wound Closure Methods for Scar Appearance

Molecular Subtyping for Metastatic Breast Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial